Hikma ‘skinny’ label does not infringe Amarin patents

Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23 March 2023 Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

More on this story

Big Pharma

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23 March 2023 Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

More on this story

Big Pharma

Amarin launches Fed Circ bid to prove Hikma generic infringed heart drug

23 March 2023 Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.

Americas

Amarin appeals ‘skinny label’ loss

23 November 2022 Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

7 April 2017 Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem.

More features

Could Apple v Masimo limit patent cases at the ITC?

Eli Lilly strikes again in weight-loss drugs fight

Novartis moves to block cancer drug generic in US

WATCH: China patent landscape—AI, patent linkage, export controls, and more

China bars USPTO employee from leaving country

UPC hands rare default win to Insulet, bans insulin pump in EU

GSK loses appeal over purple inhaler TM in Europe

Astellas defends Xtandi patent as court rejects generics’ appeal

Hikma ‘skinny’ label does not infringe Amarin patents

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features